Evidence map›Paper›PMID 42732249›Full record

ArticleInternational journal of breast cancer2026

Artificial Intelligence as an Assistive Tool in Breast Cancer Screening and Diagnosis in the Digital Era.

Manjit Kaur Rana, Amanjot Singh, Amritpal Singh Rana, Sukhchain Kaur, Aklank Jain, Astha Gupta, Upneet Kaur

Abstract read
In one paragraph

Article in International journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Manjit Kaur RanaDepartment of Pathology, All India Institute of Medical Sciences Bathinda, Bathinda, Punjab, India.ORCID https://orcid.org/0000-0003-0791-1758
Amanjot SinghDepartment of Pathology, All India Institute of Medical Sciences Bathinda, Bathinda, Punjab, India.ORCID https://orcid.org/0000-0002-6006-6285
Amritpal Singh RanaDepartment of General Surgery, All India Institute of Medical Sciences Bathinda, Bathinda, Punjab, India.ORCID https://orcid.org/0000-0002-3073-3497
Sukhchain KaurDepartment of Pathology, All India Institute of Medical Sciences Bathinda, Bathinda, Punjab, India.ORCID https://orcid.org/0000-0002-9698-3835
Aklank JainDepartment of Zoology, Central University of Punjab, Bathinda, Punjab, India, cup.ac.in.ORCID https://orcid.org/0000-0001-5539-3225
Astha GuptaDepartment of Pathology, All India Institute of Medical Sciences Bathinda, Bathinda, Punjab, India.ORCID https://orcid.org/0009-0006-6242-3924
Upneet KaurDepartment of Pathology, All India Institute of Medical Sciences Bathinda, Bathinda, Punjab, India.ORCID https://orcid.org/0009-0003-4493-0066

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Breast cancer (BC) is a worldwide health task, and its increasing frequency and the associated burden on healthcare professionals are also increasing. Hence, integrating machine learning (ML) and artificial intelligence (AI) into screening and diagnosis is irrefutable in the digital age. A comprehensive systematic review was conducted aimed at assessing the application of AI and ML techniques to enhance BC screening, diagnosis, classification, and tumor marker scoring. Methods: An electronic literature search in PubMed and google scholar by following systematic review guidelines was conducted using keywords AI, cytology, histology, tumor marker expression, deep learning (DL) and ML and carcinoma breast. Articles exclusively pertaining to BC pathology were included in the study. Results: This study reviews the AI tools incorporating advanced DL models, such as artificial neural networks (ANNs), support vector machines (SVMs), convolutional neural networks (CNNs), and faster R-CNN, which have demonstrated high accuracy in analyzing medical images from various modalities, including cytology and histopathology. AI applications also extend to combined imaging-pathology diagnostics and tumor biomarkers, showing promising outcomes for consistency, rapidity, and cost-effectiveness. Various Food and Drug Administration (FDA) and internationally approved AI software products for BC detection illustrate the translation potential of these technologies. Conclusions: The use of AI in the analysis of pathological samples in diagnosis, research, precision medicine, and patient care is increasing, and such assistance has great potential to reduce the workload of pathologists.

Indexed as

AI software validationcancer screeningHER2 scoringhistopathologytumor segmentation

Identifiers

PMID42732249
PMCPMC13570440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.